Live Breaking News & Updates on Jane Lowe Meisel

Stay updated with breaking news from Jane lowe meisel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Real-World Patient Characteristics and Treatment Patterns Associated With Tucatinib Therapy in Patients With HER2+ Metastatic Breast Cancer

Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd). ....

Jane Lowe Meisel , Real World Patient Characteristics , Patients With , Metastatic Breast , Lowe Meisel , Her2 Metastatic Breast Cancer , Tucatinib Based Treatment , Fam Trastuzumab Deruxtecan , T Dxd , Her2 Targeted Therapies , Active Brain Metasases ,

Phase 2 Data Support Development of Lasofoxifene in ESR1-mutant, ER+/HER2– Breast Cancer

Jane Lowe Meisel, MD, discusses previously reported data from the ELAINE-1 and ELAINE-2 trials, their significance within the ESR1-mutant, ER-positive, HER2-negative breast cancer treatment paradigm, and the purpose of the ongoing ELAINE-3 trial. ....

Emory University School Of Medicine , United States , Jane Lowe Meisel , Department Of Hematology , Sermonix Pharmaceuticals Inc , Sermonix Pharmaceuticals , Department Of Gynecology , Medical Oncology , Emory University School , Patients With Esr1 Mutant , Apr Positive , Her2 Negative Breast Cancer , Elaine 1 Trial , Elaine 2 Trial , Elaine 3 Study ,